These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 552840)

  • 1. [Cellular immunity in patients with Hodgkin's disease: modification induced by incubating lymphocytes with fetal calf serum and Hodgkin's serum].
    Rambotti P; Velardi A; Spinozzi F; Falini B; Martelli MF
    Boll Ist Sieroter Milan; 1979 Mar; 58(1):90-9. PubMed ID: 552840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of cell surface abnormalities of T lymphocytes in hodgkin's disease after in vitro incubation in fetal sera.
    Fuks Z; Strober S; King DP; Kaplan HS
    J Immunol; 1976 Oct; 117(4):1331-5. PubMed ID: 1086325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between serum factors and T lymphocytes in Hodgkin's disease. Use as a diagnostic test.
    Fuks Z; Strober S; Kaplan HS
    N Engl J Med; 1976 Dec; 295(23):1273-8. PubMed ID: 185517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease.
    Gajl-Peczalska KJ; Hansen JA; Bloomfield CD; Good RA
    J Clin Invest; 1973 Dec; 52(12):3064-73. PubMed ID: 4201499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E-rosette inhibiting substance in Hodgkin's disease spleen extracts.
    Bieber MM; Fuks Z; Kaplan HS
    Clin Exp Immunol; 1977 Sep; 29(3):369-75. PubMed ID: 201408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired lymphocyte transformation in Hodgkin's disease. Evidence for depletion of circulating t-lymphocytes.
    Matchett KM; Huang AT; Kremer WB
    J Clin Invest; 1973 Aug; 52(8):1908-17. PubMed ID: 4541673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease.
    Levo Y; Rotter V; Ramot B
    Biomedicine; 1975 Jun; 23(6):198-200. PubMed ID: 1082352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A micro-method for PHA-induced stimulation of human lymphocytes. II. communication: effect of splenectomy on the inhibitory activity of serum in patients with Hodgkin's disease.
    Pappas A; Pees H; Girmann G
    Z Immunitatsforsch Immunobiol; 1977 Apr; 153(1):1-10. PubMed ID: 868205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating immune complexes and serum lysozyme levels in untreated Hodgkin's disease. Their relationship to immune function.
    Spinozzi F; Velardi A; Rambotti P; Losito A; Zampi I; Cernetti C; Gerli R; Martelli MF; Grignani F
    J Clin Lab Immunol; 1983 Oct; 12(2):87-92. PubMed ID: 6644793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normal active rosette-forming-cells in untreated patients with Hodgkin's disease.
    Lang JM; Bigel P; Oberling F; Mayer S
    Biomedicine; 1977 Dec; 27(9-10):322-4. PubMed ID: 606306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired cell-mediated immunity in Hodgkin's disease mediated by suppressor lymphocytes and monocytes.
    Hillinger SM; Herzig GP
    J Clin Invest; 1978 Jun; 61(6):1620-7. PubMed ID: 149140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zinc status and cellular immunity in pediatric Hodgkin's disease.
    Cavdar AO; Babacan E; Ertem U; Gözdasoğlu S; Arcasoy A
    Prog Clin Biol Res; 1983; 129():207-20. PubMed ID: 6657703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PHA dose dependent defect in lymphocyte stimulation and E-rosette-forming cells in untreated Hodgkin's disease.
    Land JM; Litwin J; Bigel P; Oberling F; Mayer S
    Acta Haematol Pol; 1977; 8(2):131-4. PubMed ID: 329629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibitory action of Hodgkin's disease patients serum on T lymphocytes E rosette forming ability (author's transl)].
    Panteghini M; Piccioli E; Migliorati T; Ruggeri G
    Ann Sclavo; 1979; 21(4):483-93. PubMed ID: 317987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Persisting deficiency of cell mediated immunity in Hodgkin's disease in complete remission (author's transl)].
    Lang JM; Bigel P; Giron C; Faradji A; Oberling F; Mayer S
    Nouv Presse Med; 1979 Nov; 8(44):3629-32. PubMed ID: 316521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum zinc levels, lymphocyte counts and functions in pediatric Hodgkin's disease.
    Babacan E; Cavdar AO; Arcasoy A
    Boll Ist Sieroter Milan; 1977 Jul; 56(3):228-34. PubMed ID: 901636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro stimulation of T-cell rosette formation by antiserum to thymus factor in Hodgkin's disease.
    Zółtowska A; Arendt M; Gan J
    Arch Immunol Ther Exp (Warsz); 1984; 32(1):51-7. PubMed ID: 6332594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)].
    Lang JM; Bigel P; Oberling F; Mayer S
    Pathol Biol (Paris); 1978; 26(3-4):159-62. PubMed ID: 355984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)].
    Lang JM; Bigel P; Oberling F; Mayer S
    Sem Hop; 1978 Nov 8-15; 54(37-40):1155-8. PubMed ID: 217096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monocyte PGE2 secretion in Hodgkin's disease and its relation to decreased cellular immunity.
    Passwell J; Levanon M; Davidsohn J; Ramot B
    Clin Exp Immunol; 1983 Jan; 51(1):61-8. PubMed ID: 6572580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.